268 related articles for article (PubMed ID: 20818839)
1. Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Groenendaal H; Tarrants ML; Armand C
Clin Drug Investig; 2010; 30(11):789-98. PubMed ID: 20818839
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo) compared to standard care in UK Parkinson's disease patients with wearing-off.
Findley LJ; Lees A; Apajasalo M; Pitkänen A; Turunen H
Curr Med Res Opin; 2005 Jul; 21(7):1005-14. PubMed ID: 16004667
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.
Palmer CS; Nuijten MJ; Schmier JK; Subedi P; Snyder EH
Pharmacoeconomics; 2002; 20(9):617-28. PubMed ID: 12141889
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacoeconomic aspects of combined treatment of advanced stage of Parkinson's disease].
Rudakova AV; Levin OS
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6. Vyp. 2):96-100. PubMed ID: 28980620
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
Haycox A; Armand C; Murteira S; Cochran J; François C
Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.
Nuijten MJ; van Iperen P; Palmer C; van Hilten BJ; Snyder E
Value Health; 2001; 4(4):316-28. PubMed ID: 11705299
[TBL] [Abstract][Full Text] [Related]
8. Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial.
Trenkwalder C; Kuoppamäki M; Vahteristo M; Müller T; Ellmén J
Neurology; 2019 Mar; 92(13):e1487-e1496. PubMed ID: 30824559
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson's disease.
Lowin J; Sail K; Baj R; Jalundhwala YJ; Marshall TS; Konwea H; Chaudhuri KR
J Med Econ; 2017 Nov; 20(11):1207-1215. PubMed ID: 28895769
[TBL] [Abstract][Full Text] [Related]
10. The association between adherence to levodopa/carbidopa/entacapone therapy and healthcare utilization and costs among patients with Parkinson's disease: a retrospective claims-based analysis.
Delea TE; Thomas SK; Hagiwara M
CNS Drugs; 2011 Jan; 25(1):53-66. PubMed ID: 21128694
[TBL] [Abstract][Full Text] [Related]
11. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Stocchi F; Rabey JM
Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales.
Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B
J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353
[TBL] [Abstract][Full Text] [Related]
13. Factors determining when to start levodopa/carbidopa/entacapone treatment in Spanish patients with Parkinson's disease.
Martínez-Martín P; Hernández B; Ricart J;
Neurologia; 2014 Apr; 29(3):153-60. PubMed ID: 23465686
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa.
Hansen RN; Suh K; Serbin M; Yonan C; Sullivan SD
J Med Econ; 2021; 24(1):563-569. PubMed ID: 33866942
[TBL] [Abstract][Full Text] [Related]
15. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Hauser RA; Panisset M; Abbruzzese G; Mancione L; Dronamraju N; Kakarieka A;
Mov Disord; 2009 Mar; 24(4):541-50. PubMed ID: 19058133
[TBL] [Abstract][Full Text] [Related]
16. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of levodopa/carbidopa intestinal gel compared to standard care in late stage Parkinson's disease in the UK.
Lowin J; Bergman A; Chaudhuri KR; Findley LJ; Roeder C; Schifflers M; Wood E; Morris S
J Med Econ; 2011; 14(5):584-93. PubMed ID: 21728911
[TBL] [Abstract][Full Text] [Related]
18. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.
Stocchi F; Rascol O; Kieburtz K; Poewe W; Jankovic J; Tolosa E; Barone P; Lang AE; Olanow CW
Ann Neurol; 2010 Jul; 68(1):18-27. PubMed ID: 20582993
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson's disease in the UK and Germany.
Walter E; Odin P
J Med Econ; 2015 Feb; 18(2):155-65. PubMed ID: 25348011
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
